Report Detail
Global Gastric Cancer Diagnostics Market Growth (Status and Outlook) 2023-2029
- RnM4529316 |
- 17 April, 2023 |
- Global |
- 109 Pages |
- GIR (Global Info Research) |
- Service & Software
The global Gastric Cancer Diagnostics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Gastric Cancer Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gastric Cancer Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gastric Cancer Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gastric Cancer Diagnostics players cover Myriad Genetics, ACON Laboratories, Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific, F. Hoffmann-La Roche and General Electric, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Gastric Cancer Diagnostics Industry Forecast” looks at past sales and reviews total world Gastric Cancer Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Gastric Cancer Diagnostics sales for 2023 through 2029. With Gastric Cancer Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastric Cancer Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Gastric Cancer Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gastric Cancer Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastric Cancer Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastric Cancer Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastric Cancer Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Gastric Cancer Diagnostics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Instrument
Reagent Consumables
Service
Segmentation by application
Male
Female
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Myriad Genetics
ACON Laboratories
Teco Diagnostics
Vela Diagnostics
Abbott, AdvaCare Pharma
Fujirebio (An H.U. Group company)
Thermo Fisher Scientific
F. Hoffmann-La Roche
General Electric
Agilent Technologies
Endofotonics
Biohit Oyj
BIOCEPT
FOUNDATION MEDICINE
DiaSorin S.p.A
Paragon Genomics
BIOMÉRIEUX
QIAGEN
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Gastric Cancer Diagnostics Market Size 2018-2029
- 2.1.2 Gastric Cancer Diagnostics Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Gastric Cancer Diagnostics Segment by Type
- 2.2.1 Instrument
- 2.2.2 Reagent Consumables
- 2.2.3 Service
- 2.3 Gastric Cancer Diagnostics Market Size by Type
- 2.3.1 Gastric Cancer Diagnostics Market Size CAGR by Type (2018 VS 2022 VS 2029)
- 2.3.2 Global Gastric Cancer Diagnostics Market Size Market Share by Type (2018-2023)
- 2.4 Gastric Cancer Diagnostics Segment by Application
- 2.4.1 Male
- 2.4.2 Female
- 2.5 Gastric Cancer Diagnostics Market Size by Application
- 2.5.1 Gastric Cancer Diagnostics Market Size CAGR by Application (2018 VS 2022 VS 2029)
- 2.5.2 Global Gastric Cancer Diagnostics Market Size Market Share by Application (2018-2023)
3 Gastric Cancer Diagnostics Market Size by Player
- 3.1 Gastric Cancer Diagnostics Market Size Market Share by Players
- 3.1.1 Global Gastric Cancer Diagnostics Revenue by Players (2018-2023)
- 3.1.2 Global Gastric Cancer Diagnostics Revenue Market Share by Players (2018-2023)
- 3.2 Global Gastric Cancer Diagnostics Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Gastric Cancer Diagnostics by Regions
- 4.1 Gastric Cancer Diagnostics Market Size by Regions (2018-2023)
- 4.2 Americas Gastric Cancer Diagnostics Market Size Growth (2018-2023)
- 4.3 APAC Gastric Cancer Diagnostics Market Size Growth (2018-2023)
- 4.4 Europe Gastric Cancer Diagnostics Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Gastric Cancer Diagnostics Market Size Growth (2018-2023)
5 Americas
- 5.1 Americas Gastric Cancer Diagnostics Market Size by Country (2018-2023)
- 5.2 Americas Gastric Cancer Diagnostics Market Size by Type (2018-2023)
- 5.3 Americas Gastric Cancer Diagnostics Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Gastric Cancer Diagnostics Market Size by Region (2018-2023)
- 6.2 APAC Gastric Cancer Diagnostics Market Size by Type (2018-2023)
- 6.3 APAC Gastric Cancer Diagnostics Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Gastric Cancer Diagnostics by Country (2018-2023)
- 7.2 Europe Gastric Cancer Diagnostics Market Size by Type (2018-2023)
- 7.3 Europe Gastric Cancer Diagnostics Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Gastric Cancer Diagnostics by Region (2018-2023)
- 8.2 Middle East & Africa Gastric Cancer Diagnostics Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Gastric Cancer Diagnostics Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Gastric Cancer Diagnostics Market Forecast
- 10.1 Global Gastric Cancer Diagnostics Forecast by Regions (2024-2029)
- 10.1.1 Global Gastric Cancer Diagnostics Forecast by Regions (2024-2029)
- 10.1.2 Americas Gastric Cancer Diagnostics Forecast
- 10.1.3 APAC Gastric Cancer Diagnostics Forecast
- 10.1.4 Europe Gastric Cancer Diagnostics Forecast
- 10.1.5 Middle East & Africa Gastric Cancer Diagnostics Forecast
- 10.2 Americas Gastric Cancer Diagnostics Forecast by Country (2024-2029)
- 10.2.1 United States Gastric Cancer Diagnostics Market Forecast
- 10.2.2 Canada Gastric Cancer Diagnostics Market Forecast
- 10.2.3 Mexico Gastric Cancer Diagnostics Market Forecast
- 10.2.4 Brazil Gastric Cancer Diagnostics Market Forecast
- 10.3 APAC Gastric Cancer Diagnostics Forecast by Region (2024-2029)
- 10.3.1 China Gastric Cancer Diagnostics Market Forecast
- 10.3.2 Japan Gastric Cancer Diagnostics Market Forecast
- 10.3.3 Korea Gastric Cancer Diagnostics Market Forecast
- 10.3.4 Southeast Asia Gastric Cancer Diagnostics Market Forecast
- 10.3.5 India Gastric Cancer Diagnostics Market Forecast
- 10.3.6 Australia Gastric Cancer Diagnostics Market Forecast
- 10.4 Europe Gastric Cancer Diagnostics Forecast by Country (2024-2029)
- 10.4.1 Germany Gastric Cancer Diagnostics Market Forecast
- 10.4.2 France Gastric Cancer Diagnostics Market Forecast
- 10.4.3 UK Gastric Cancer Diagnostics Market Forecast
- 10.4.4 Italy Gastric Cancer Diagnostics Market Forecast
- 10.4.5 Russia Gastric Cancer Diagnostics Market Forecast
- 10.5 Middle East & Africa Gastric Cancer Diagnostics Forecast by Region (2024-2029)
- 10.5.1 Egypt Gastric Cancer Diagnostics Market Forecast
- 10.5.2 South Africa Gastric Cancer Diagnostics Market Forecast
- 10.5.3 Israel Gastric Cancer Diagnostics Market Forecast
- 10.5.4 Turkey Gastric Cancer Diagnostics Market Forecast
- 10.5.5 GCC Countries Gastric Cancer Diagnostics Market Forecast
- 10.6 Global Gastric Cancer Diagnostics Forecast by Type (2024-2029)
- 10.7 Global Gastric Cancer Diagnostics Forecast by Application (2024-2029)
11 Key Players Analysis
- 11.1 Myriad Genetics
- 11.1.1 Myriad Genetics Company Information
- 11.1.2 Myriad Genetics Gastric Cancer Diagnostics Product Offered
- 11.1.3 Myriad Genetics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Myriad Genetics Main Business Overview
- 11.1.5 Myriad Genetics Latest Developments
- 11.2 ACON Laboratories
- 11.2.1 ACON Laboratories Company Information
- 11.2.2 ACON Laboratories Gastric Cancer Diagnostics Product Offered
- 11.2.3 ACON Laboratories Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 ACON Laboratories Main Business Overview
- 11.2.5 ACON Laboratories Latest Developments
- 11.3 Teco Diagnostics
- 11.3.1 Teco Diagnostics Company Information
- 11.3.2 Teco Diagnostics Gastric Cancer Diagnostics Product Offered
- 11.3.3 Teco Diagnostics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.3.4 Teco Diagnostics Main Business Overview
- 11.3.5 Teco Diagnostics Latest Developments
- 11.4 Vela Diagnostics
- 11.4.1 Vela Diagnostics Company Information
- 11.4.2 Vela Diagnostics Gastric Cancer Diagnostics Product Offered
- 11.4.3 Vela Diagnostics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.4.4 Vela Diagnostics Main Business Overview
- 11.4.5 Vela Diagnostics Latest Developments
- 11.5 Abbott, AdvaCare Pharma
- 11.5.1 Abbott, AdvaCare Pharma Company Information
- 11.5.2 Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Product Offered
- 11.5.3 Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.5.4 Abbott, AdvaCare Pharma Main Business Overview
- 11.5.5 Abbott, AdvaCare Pharma Latest Developments
- 11.6 Fujirebio (An H.U. Group company)
- 11.6.1 Fujirebio (An H.U. Group company) Company Information
- 11.6.2 Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Product Offered
- 11.6.3 Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.6.4 Fujirebio (An H.U. Group company) Main Business Overview
- 11.6.5 Fujirebio (An H.U. Group company) Latest Developments
- 11.7 Thermo Fisher Scientific
- 11.7.1 Thermo Fisher Scientific Company Information
- 11.7.2 Thermo Fisher Scientific Gastric Cancer Diagnostics Product Offered
- 11.7.3 Thermo Fisher Scientific Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.7.4 Thermo Fisher Scientific Main Business Overview
- 11.7.5 Thermo Fisher Scientific Latest Developments
- 11.8 F. Hoffmann-La Roche
- 11.8.1 F. Hoffmann-La Roche Company Information
- 11.8.2 F. Hoffmann-La Roche Gastric Cancer Diagnostics Product Offered
- 11.8.3 F. Hoffmann-La Roche Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.8.4 F. Hoffmann-La Roche Main Business Overview
- 11.8.5 F. Hoffmann-La Roche Latest Developments
- 11.9 General Electric
- 11.9.1 General Electric Company Information
- 11.9.2 General Electric Gastric Cancer Diagnostics Product Offered
- 11.9.3 General Electric Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.9.4 General Electric Main Business Overview
- 11.9.5 General Electric Latest Developments
- 11.10 Agilent Technologies
- 11.10.1 Agilent Technologies Company Information
- 11.10.2 Agilent Technologies Gastric Cancer Diagnostics Product Offered
- 11.10.3 Agilent Technologies Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.10.4 Agilent Technologies Main Business Overview
- 11.10.5 Agilent Technologies Latest Developments
- 11.11 Endofotonics
- 11.11.1 Endofotonics Company Information
- 11.11.2 Endofotonics Gastric Cancer Diagnostics Product Offered
- 11.11.3 Endofotonics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.11.4 Endofotonics Main Business Overview
- 11.11.5 Endofotonics Latest Developments
- 11.12 Biohit Oyj
- 11.12.1 Biohit Oyj Company Information
- 11.12.2 Biohit Oyj Gastric Cancer Diagnostics Product Offered
- 11.12.3 Biohit Oyj Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.12.4 Biohit Oyj Main Business Overview
- 11.12.5 Biohit Oyj Latest Developments
- 11.13 BIOCEPT
- 11.13.1 BIOCEPT Company Information
- 11.13.2 BIOCEPT Gastric Cancer Diagnostics Product Offered
- 11.13.3 BIOCEPT Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.13.4 BIOCEPT Main Business Overview
- 11.13.5 BIOCEPT Latest Developments
- 11.14 FOUNDATION MEDICINE
- 11.14.1 FOUNDATION MEDICINE Company Information
- 11.14.2 FOUNDATION MEDICINE Gastric Cancer Diagnostics Product Offered
- 11.14.3 FOUNDATION MEDICINE Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.14.4 FOUNDATION MEDICINE Main Business Overview
- 11.14.5 FOUNDATION MEDICINE Latest Developments
- 11.15 DiaSorin S.p.A
- 11.15.1 DiaSorin S.p.A Company Information
- 11.15.2 DiaSorin S.p.A Gastric Cancer Diagnostics Product Offered
- 11.15.3 DiaSorin S.p.A Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.15.4 DiaSorin S.p.A Main Business Overview
- 11.15.5 DiaSorin S.p.A Latest Developments
- 11.16 Paragon Genomics
- 11.16.1 Paragon Genomics Company Information
- 11.16.2 Paragon Genomics Gastric Cancer Diagnostics Product Offered
- 11.16.3 Paragon Genomics Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.16.4 Paragon Genomics Main Business Overview
- 11.16.5 Paragon Genomics Latest Developments
- 11.17 BIOMÉRIEUX
- 11.17.1 BIOMÉRIEUX Company Information
- 11.17.2 BIOMÉRIEUX Gastric Cancer Diagnostics Product Offered
- 11.17.3 BIOMÉRIEUX Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.17.4 BIOMÉRIEUX Main Business Overview
- 11.17.5 BIOMÉRIEUX Latest Developments
- 11.18 QIAGEN
- 11.18.1 QIAGEN Company Information
- 11.18.2 QIAGEN Gastric Cancer Diagnostics Product Offered
- 11.18.3 QIAGEN Gastric Cancer Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
- 11.18.4 QIAGEN Main Business Overview
- 11.18.5 QIAGEN Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Gastric Cancer Diagnostics. Industry analysis & Market Report on Gastric Cancer Diagnostics is a syndicated market report, published as Global Gastric Cancer Diagnostics Market Growth (Status and Outlook) 2023-2029
. It is complete Research Study and Industry Analysis of Gastric Cancer Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
